Abstract: The present invention provides a method of treating or ameliorating a neurodegenerative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ABC transporter inhibitor, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated in the mammal. In certain embodiments, the neurodegenerative disease comprises at least one selected from the group consisting of spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, a tauopathy, and chronic traumatic encephalopathy.
Type:
Application
Filed:
December 9, 2014
Publication date:
October 20, 2016
Applicant:
Thomas Jefferson University
Inventors:
Davide TROTTI, Piera PASINELLI, Michael R. JABLONSKI
Abstract: The present disclosure relates to methods of affecting platelet activation by the use of a PC-TP inhibitor. The PC-TP inhibitor can be administered to a subject in need thereof in order to prevent or treat pathologic thrombosis, or to treat a disorder treatable by a PAR4 inhibitor.
Abstract: Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.
Abstract: Screening and diagnostic reagents, kits and methods for primary and or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach for esophageal cancer are disclosed.
Type:
Grant
Filed:
October 22, 2014
Date of Patent:
August 30, 2016
Assignee:
Thomas Jefferson University
Inventors:
Scott A. Waldman, Jason Park, Stephanie Schulz
Abstract: The technology described herein relates to pinacolyl boronate substituted stilbenes for the treatment of cancers, e.g. cancers expressing abnormally high levels of SREBP 1.
Abstract: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
July 19, 2016
Assignee:
Thomas Jefferson University
Inventors:
Scott A. Waldman, Adam E. Snook, Michael S. Magee
Abstract: In accordance with one embodiment, a device for performing an angled craniotome includes an elongate handle, a footplate, a stem, and an elongate cutting bit. The elongate handle extends in a vertical direction. The footplate is spaced apart from the elongate handle and defines a plane generally perpendicular to the vertical direction. The footplate is offset from the handle in a horizontal direction where the horizontal direction is perpendicular to the vertical direction. The stem has a proximal end and a distal end. The proximal end is coupled to the handle and the distal end is coupled to the footplate. The stem extends from the handle at an oblique angle in the horizontal direction relative to the handle. The elongate cutting bit is coupled to the handle and extends from the handle toward the footplate at the oblique angle in the horizontal direction relative to the handle.
Type:
Application
Filed:
September 6, 2014
Publication date:
July 7, 2016
Applicants:
Thomas Jefferson University, Thomas Jefferson University Hospital, Inc.
Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression of cavcolin-1, cavcolin-2, vimentin, calponon2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.
Type:
Application
Filed:
December 10, 2015
Publication date:
May 19, 2016
Applicant:
Thomas Jefferson University
Inventors:
Michael P. Lisanti, Federica Sotgia, Richard G. Pestell
Abstract: The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RAR? agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Abstract: This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject's glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject's glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject's glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide.
Abstract: This invention relates to a method for detecting shed or circulating tumor cells in a biological fluid using labeled pituitary adenylate cyclase activating peptide or vasoactive intestinal peptide.
Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of the non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides methods for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.
Type:
Grant
Filed:
June 23, 2014
Date of Patent:
February 2, 2016
Assignees:
INSTITUT PASTEUR, THOMAS JEFFERSON UNIVERSITY
Inventors:
Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
Abstract: Methods and systems include a long-term implantable ultra-filtrate monitoring system that uses micro-porous membranes to produce an ultra-filtrate of tissue interstitial fluid or blood plasma. The ultra-filtrate is transported through a sensor to detect a level of analyte in the ultra-filtrate. The long-term implantable fluid monitoring system thus includes a first porous catheter, a second porous catheter, a sensor configured to measure an amount of analyte in fluid, and a pump configured to move fluid through the first porous catheter to the sensor and from the sensor through the second porous catheter.
Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding.
Type:
Grant
Filed:
April 26, 2013
Date of Patent:
October 13, 2015
Assignee:
Thomas Jefferson University
Inventors:
Scott A. Waldman, Michael S. Magee, Adam E. Snook
Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
Type:
Grant
Filed:
May 19, 2014
Date of Patent:
October 6, 2015
Assignee:
Thomas Jefferson University
Inventors:
Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
Abstract: Presented herein is a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an agent that inhibits the MSF/Cdc42/NFkB cascade in the subject's tumor-associated fibroblasts.
Abstract: An immune response in a subject is elicited by a regiment comprising immunization with an attenuated recombinant rabies virus encoding at least one foreign protein antigen, and booster immunization with the at least one foreign protein antigen in a vehicle that does not contain adjuvant. The foreign protein antigen may comprise a prion protein antigen, a cancer-associated antigens, a viral antigen, a bacterial antigens, or a protozoal antigen. The prime/boost regimen produces predominantly IgG 2A/C and IgG 2B antibodies against the foreign protein antigen, indicating a TH1 response. Rabies virus attenuation may be provided, for example, by one or more mutations in the rabies glycoprotein gene which confers attenuation of pathogenicity.
Type:
Application
Filed:
September 24, 2013
Publication date:
July 30, 2015
Applicant:
THOMAS JEFFERSON UNIVERSITY
Inventors:
Bernhard Dietzschold, Douglas Craig Hooper, Milosz Faber
Abstract: Prostate cancer and hematological neoplasms are treated by administration of (i) a compound of Formula I: wherein: R1 is —OH or —O—P(O)(OH)2; and R2 is (II) or (III); (ii) N6-benzyladenosine, (iii) N-(phenylmethyl)-7-?-D-ribofuranosyl-7H-pyrrolo [2,3 -d]pyrimidin-4-amine, (iv) N-(phenylmethyl)-7?-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5?-monophosphate; or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
May 10, 2013
Publication date:
July 30, 2015
Applicant:
THOMAS JEFFERSON UNIVERSITY
Inventors:
Marja Tuuli Nevalainen, Vincent C. O. Njar, Zhiyong Liao, Allen B. Reitz, Mark E. McDonnell
Abstract: Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C8-C16 alkyl group. The long chain N-alkyl compounds and oxa-substituted derivatives thereof can be used in the treatment of viral infections, in particular hepatitis B virus or hepatitis C virus, in a cell or an individual. For example, the long chain N-alkyl compounds or oxa-substituted derivatives thereof can be derived from piperidines, pyrrolidines, phenylamines, pyridines, pyrroles, or amino acids.
Type:
Grant
Filed:
March 7, 2011
Date of Patent:
July 28, 2015
Assignees:
Thomas Jefferson University, The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics Corporation
Inventors:
Nicole Zitzmann, Terry D. Butters, Frances M. Platt, Gary S. Jacob, Donald H. Picker, Sandra Carrouee, George W. J. Fleet, Raymond A. Dwek, David Durantel, Anand Mehta, Timothy M. Block